NasdaqGS:MDGLBiotechs
Madrigal Expands MASH Franchise With Precision RNAi License For ARO PNPLA3
Madrigal Pharmaceuticals (NasdaqGS:MDGL) has secured an exclusive worldwide license to ARO-PNPLA3, an RNAi therapy for MASH, from Arrowhead Pharmaceuticals.
The program is in clinical development, with Phase 1 data indicating substantial liver fat reduction and a favorable safety profile in a genetically defined MASH population.
The deal expands Madrigal's pipeline beyond Rezdiffra and adds a precision medicine angle to its MASH franchise.
Madrigal Pharmaceuticals enters this agreement with...